Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis - Wikidata - awgldk - TriplyDB

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

http://www.wikidata.org/entity/Q28366838

about

Quality of outcome reporting in phase II studies in pulmonary tuberculosis Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy.Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.Monitoring therapeutic efficacy by real-time detection of Mycobacterium tuberculosis mRNA in sputum In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus Future novel therapeutic agents for Clostridium difficile infection.Recent developments in the treatment of tuberculosis.Early bactericidal activity of antituberculosis agents.New advances in antibiotic development and discovery.Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis.Development potential of rifalazil and other benzoxazinorifamycins.Antibacterial activity of rifamycins for M. smegmatis with comparison of oxidation and binding to tear lipocalin.Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.The early bactericidal activity of antituberculosis drugs.The future for early-stage tuberculosis drug discovery Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells Interaction of rifalazil with oxidant-generating systems of human polymorphonuclear neutrophils.Assessment of the Efficacy of New Anti-Tuberculosis Drugs.

P2860

Q26777160-5DD5DFC9-8E31-4E54-946B-7003A37B3D76 Q33614197-98A2E73A-F524-476C-9E2A-F667285EA215 Q33797986-9E4EAB9D-6866-4732-A0B9-BC7AFD074187 Q33867418-078A6727-63F5-404A-A028-6624E911375E Q34509698-8DC4176D-A740-4E26-85BC-12C1F733BA67 Q35175136-9943BEF1-26FD-4857-8DE1-26649EDB82CC Q35185753-3146CA73-2DB6-44BD-96CC-45B55BFDBA24 Q35917156-E2CC7086-1707-4ED3-8D82-B91EB69DDD43 Q36065983-988A7F73-44F3-4CAD-A693-C6D736C6F9CE Q36314493-8ABCB424-4283-4537-A5C9-51D3257DDDDC Q36491823-E7D21132-0CF5-4A59-BAD9-C0F81DB5BF5A Q37711225-90EDB2DB-A3EF-4CD9-A950-191254119839 Q37865419-F99616D6-2FCE-44FD-B5BF-6B94B5F1F40A Q37865423-BC9DC8C7-47FF-4B41-98FB-33D10CB3DC01 Q37870051-6418F667-A452-4A71-8146-01A795084B8C Q38176039-93991A38-3EE1-435A-A5CC-3C6575DF650C Q38358621-03D3E029-7C64-4637-9AF5-8FE661511389 Q39078400-26AEBB56-1C40-4E51-885F-8B55A8AC0853 Q39651290-D66613CE-47D7-493F-945F-907B1DB81342 Q40668074-7982F75B-FD91-479D-B1BD-9A4FC5EEE07F Q41572870-FB93801A-3E90-48D5-B56E-BA1604347402

P2860

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

http://www.wikidata.org/entity/Q28366838

description

2001 nî lūn-bûn

@nan

2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

@ast

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

@en

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

@nl

type

label

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

@ast

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

@en

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

@nl

prefLabel

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

@ast

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

@en

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

@nl

P1433

Q28366838-C18D00C0-A04B-4197-8836-2C41AD0489E8

P1476

Q28366838-58E0992D-6F05-453E-A3A9-6F9A629D685B

P2093

Q28366838-111EDA7A-2F3D-465B-8CE9-A17E4A352785

Q28366838-535F9698-DBE4-4788-BA55-FE31C9A7502B

Q28366838-55F15A00-4092-46DC-9450-9F07A0C912DA

Q28366838-75FAEA84-69C4-4B9A-985E-10938DF4A03C

Q28366838-9F84377B-15A6-4F03-AC7A-7F3B31F7712F

Q28366838-B3900EEE-88CD-433A-94EA-75C317A46CE8

Q28366838-B4188950-4179-41A6-AB45-6E892A0B1AE6

Q28366838-FA6FF1A0-300B-4E20-9FAD-B74CCC6BD319

P2860

Q28366838-01F4CAEF-E894-413F-BB3B-5894FDC0D27D

Q28366838-4FE3D10D-45AE-4016-A56B-4CFE95221074

Q28366838-58FE2E57-837F-4B72-A1B3-7CB9A250FFE4

Q28366838-5B6A91A0-62DE-4AAF-8067-0030EAB2D093

Q28366838-629A554C-D319-4731-AAB0-9495200E6089

Q28366838-63851364-4C70-4AF5-AAA1-46C409A0B58C

Q28366838-63B59298-AD92-4072-B938-507046315B61

Q28366838-904B9CFB-6AC5-4781-9550-5E07AD71C097

Q28366838-99365866-875C-49CF-9A70-E24AF8689B1A

Q28366838-B81EF520-AEE5-40ED-BA21-25EA971F0F37

P304

Q28366838-5F5F4384-0B0D-4F58-8006-EFC9DD4AEAEF

P31

Q28366838-8FBCD71A-4127-4881-B71F-8A56A015D1C3

P356

Q28366838-61A28E0E-2A32-4F1D-B191-90CCE4F63591

P407

Q28366838-6AC39FEE-D283-4390-9B31-65246682C5FF

P433

Q28366838-BB31606F-E9DA-4AA1-9AD0-EA5A67480D74

P478

Q28366838-B389D73D-4B4A-4738-BE89-A1879F27E6F6

P50

Q28366838-C7EE4A4B-2B8A-4225-8B93-CEACD262C2F6

P577

Q28366838-05414E5A-A650-425E-BF8C-3FDD7417120B

P698

Q28366838-EE7A591E-4CDF-4E16-8E67-61E10A1A3B17

P921

Q28366838-C5F567DE-3148-428F-AF6D-C7A17C183DC5

Q28366838-E8E91473-1C7E-473E-93BE-A23CC27DF9CF

P932

Q28366838-9ED373DB-7AEC-4AA0-9272-5447D229FF66

P356

AAC.45.7.1972-1976.2001

P1433

Antimicrobial Agents and Chemotherapy

P1476

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

@en

P2093

C Wells

http://www.w3.org/2001/XMLSchema#string

J L Johnson

http://www.w3.org/2001/XMLSchema#string

K Eisenach

http://www.w3.org/2001/XMLSchema#string

L M Rocha

http://www.w3.org/2001/XMLSchema#string

L Rose

http://www.w3.org/2001/XMLSchema#string

L Teixeira

http://www.w3.org/2001/XMLSchema#string

M Palaci

http://www.w3.org/2001/XMLSchema#string

R Dietze

http://www.w3.org/2001/XMLSchema#string

P2860

Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. China Tuberculosis Control Collaboration

In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis

Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model

Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis

Leucopenia caused by two rifampicin preparations.

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids.

Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment.

Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs.

Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay

The early bactericidal activity of drugs in patients with pulmonary tuberculosis.

P304

1972-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.45.7.1972-1976.2001

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

P577

2001-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11408210

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

infectious disease

P932

90587

http://www.w3.org/2001/XMLSchema#string